| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensi...
Kimberly-Clark is still "oversold after the Kenvue announcement," Jenny Van Leeuwen Harrington says, citing its 5% divi...
First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved lab...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has...
Roark eyes a $2B deal for Nothing Bundt Cakes; Forge Global explores a buyer; Dr. Phil's media firm faces liquidation.
Argus Research analyst David Toung maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from...